You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 11, 2025

List of Excipients in API levocarnitine


✉ Email this page to a colleague

« Back to Dashboard


Excipients in NDA-approved (novel) drugs containing levocarnitine

Glossary
Company Tradename Ingredient NDC Excipient Potential Generic Entry
Akorn LEVOCARNITINE levocarnitine 50383-171 CHERRY
Akorn LEVOCARNITINE levocarnitine 50383-171 MALIC ACID
Akorn LEVOCARNITINE levocarnitine 50383-171 METHYLPARABEN
Akorn LEVOCARNITINE levocarnitine 50383-171 PROPYLPARABEN
Akorn LEVOCARNITINE levocarnitine 50383-171 SUCROSE
>Company >Tradename >Ingredient >NDC >Excipient >Potential Generic Entry

Subscribe to access the full database, or Get Started Free

Excipients in ANDA-approved (generic) drugs containing levocarnitine

Company Ingredient NDC Excipient
Hikma Pharmaceuticals USA Inc levocarnitine 0143-9852 HYDROCHLORIC ACID
Hikma Pharmaceuticals USA Inc levocarnitine 0143-9852 SODIUM HYDROXIDE
American Regent Inc levocarnitine 0517-1045 HYDROCHLORIC ACID
American Regent Inc levocarnitine 0517-1045 SODIUM HYDROXIDE
American Regent Inc levocarnitine 0517-1045 WATER
>Company >Ingredient >NDC >Excipient

Subscribe to access the full database, or Get Started Free

Detailed excipient profiles for levocarnitine

Excipient focus: ALCOHOL

Excipient focus: CELLULOSE, MICROCRYSTALLINE

Excipient focus: CHERRY

Excipient focus: HYDROCHLORIC ACID

Excipient focus: MAGNESIUM STEARATE

Excipient focus: MALIC ACID

Excipient focus: METHYLPARABEN

Excipient focus: POVIDONE

Excipient focus: POVIDONE K30

Excipient focus: PROPYLPARABEN

Excipient focus: SACCHARIN SODIUM

Excipient focus: SODIUM HYDROXIDE

Excipient focus: SODIUM STARCH GLYCOLATE TYPE A

Excipient focus: SUCROSE

Excipient focus: WATER

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

 
© Copyright 2002-2025 thinkBiotech LLC
ISSN: 2162-2639
Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2025 - 2026
 NCE-1 Patent Challenge Dates 2025 - 2026
Preferred Citation:

Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2025, www.DrugPatentWatch.com.
   See Primary Research Papers Citing DrugPatentWatch

Links